亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

濟南宏方德醫藥科技有限公司(銷售三部)  

沒有填寫主營業務~~

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:王紅
  • 電話:0531-55505896
  • QQ:2659530578
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 119302-91-9
119302-91-9
單價 20.00 / 千克對比
銷量 暫無
發貨 山東濟南市付款后3天內
庫存 9000千克起訂1千克
品牌 濟南宏方德
型號 119302-91-9
規格 千克
過期 長期有效
更新 2014-04-08 09:19
 
詳細信息

【中文】

羅庫溴銨
【英文名稱】

[3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enyl-2,3,4,5-tetrahydropyrrol-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate bromide
ROCURONIUM BROMIDE
ROCURONIUN BROMIDE
1-[(2b,3a,5a,16b,17b)-17-(Acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl]-1-(2-propenyl)pyrrolidinium Bromide
Esmeron
Org-9426
Zemuron
Rocuronium Bromide/1-[17B-(acetyloxy)-3a-hydroxy2B-(4-morpholinyl)-5a-androstan-16B-yl]-1-(2-propenyl)pyrrolidinium bromide
[3-Hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enyl-2,3,4,5-tetrahydropyrrol-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate bromide
1-[17B-(acetyloxy)-3a-hydroxy2B-(4-morpholinyl)-5a -androstan-16B-yl]-1-(2-propenyl)pyrrolidinium bromide
1-[17B-(acetyloxy)-3a-hydroxy-2B-(4-morpholinyl)-
1-[(2,3a,5a,16,17)-17-(Acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl]-1-(2-propenyl)pyrrolidinium Bromide
1-[(2β,3α,5α,16β,17β)-17-(Acetyloxy)-3-hydroxy-2-(4-morpholinyl)andrcstan-16-y1]-1-propenylpyrrolidinium bromide
Esmeron:Zemuron
Eslax
【CAS】

119302-91-9
【中文名稱】

羅庫溴銨
羅庫溴銨(肌松藥)
L-[(2Β,3Α,5Α,16Β,17Β)-17-(乙酰氧基)-3-羥基-2-(4-嗎啉基)雄甾-16-基]-1-丙烯基吡咯銨溴化物
【分子式】

C32H53BrN2O4
【MDL 編號】

MFCD00867768
【分子量】

609.68
【MOL 文件】

119302-91-9.mol
©2025 濟南宏方德醫藥科技有限公司(銷售三部) 版權所有   技術支持:化工網   訪問量:7742  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |